Asset Details
Do you wish to reserve the book?
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Do you wish to request the book?
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
2024
Overview
Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood of patients with MM (
n
= 28) and B-cell chronic lymphoproliferative disorders (
n
= 53) vs. health care practitioners (
n
= 96), using multidimensional and computational flow cytometry. MM patients displayed altered distribution of most cell types (41/56, 73%), particularly within the B-cell (17/17) and T-cell (20/30) compartments. Using COVID-19 as a case study, we compared the immune response to vaccination based on 64,304 data points generated from the analysis of 1099 longitudinal samples. MM patients showed limited B-cell expansion linked to lower anti-RBD and anti-S antibody titers after the first two doses and booster. The percentages of B cells and CD4
+
T cells in the blood, as well as the absolute counts of B cells and dendritic cells, predicted vaccine immunogenicity at different time points. In contrast with the humoral response, the percentage and antigen-dependent differentiation of SARS-CoV-2-specific CD8
+
T cells was not altered in MM patients. Taken together, this study defined the cellular composition associated with immune dysfunction in MM and provided biomarkers such as the B-cell percentage and absolute count to individualize vaccination calendars.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
/ 13/31
/ Aged
/ Antibodies, Viral - immunology
/ Biomedical and Life Sciences
/ CD4-Positive T-Lymphocytes - immunology
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - administration & dosage
/ COVID-19 Vaccines - immunology
/ Female
/ Humans
/ Male
/ Multiple Myeloma - immunology
/ Oncology
